首页> 外文期刊>Pharmaceutical patent analyst >Misleading data in pharmaceutical and biological patent specifications: best mode after the America Invents Act
【24h】

Misleading data in pharmaceutical and biological patent specifications: best mode after the America Invents Act

机译:药品和生物专利规范中的数据令人误解:《美国发明法》之后的最佳模式

获取原文
获取原文并翻译 | 示例
           

摘要

Several years ago, the corresponding author of this article obtained a judgment of invalidity of two US biotechnology patents — and inequitable conduct as to one of them - based on a failure to disclose the best mode of carrying out the invention. The case, entitled Ajinomoto v. International Trade Commission, revolved around the fact, determined through discovery, that the experimental results set forth in the patents were fictional.
机译:几年前,本文的通讯作者基于未能披露实施本发明的最佳方式而判定两项美国生物技术专利无效以及其中一项行为不公平。该案名为“ Ajinomoto诉国际贸易委员会”,围绕通过发现确定的事实,即专利中提出的实验结果是虚构的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号